Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation

Launched by UNIVERSITY OF AARHUS · Mar 12, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called radio frequency ablation (RFA) to see if it can help improve survival for patients with liver metastases from colorectal cancer. The goal is to find out if using RFA alongside surgery can boost the immune system's ability to fight cancer, potentially leading to better outcomes for patients who are undergoing surgery to remove these liver tumors.

To participate in this trial, patients need to be between the ages of 65 and 74 and have colorectal liver metastases that are planned for surgical removal. They should have at least one tumor that is 3 centimeters or larger and be in good overall health (performance status 0-1). However, patients with liver cirrhosis, cancer that has spread beyond the liver, other cancers diagnosed within the last five years, or those who have already received RFA treatment are not eligible. Participants can expect to receive the RFA treatment before their surgery and will be closely monitored throughout the trial to assess its effectiveness. This study is currently recruiting participants, so it’s an opportunity for eligible patients to take part in important research that may benefit future cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with colorectal liver metastases planned for resection
• • At least one tumor size \>=3cm
• • Performance status 0-1
• Exclusion Criteria:
• • Liver cirrhosis
• • Extrahepatic metastases that can not be addressed curatively
• • Other malignant diseases within 5 years prior to diagnosis
• • Prior RFA treatment